Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy Journal Article


Authors: Zheng, H.; Zeltsman, M.; Zauderer, M. G.; Eguchi, T.; Vaghjiani, R. G.; Adusumilli, P. S.
Article Title: Chemotherapy-induced immunomodulation in non-small-cell lung cancer: A rationale for combination chemoimmunotherapy
Abstract: Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains ≤20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC. © 2017 Future Medicine Ltd.
Keywords: chemotherapy; immunotherapy; immunomodulation; microenvironment; non-small-cell lung cancer
Journal Title: Immunotherapy
Volume: 9
Issue: 11
ISSN: 1750-743X
Publisher: Future Medicine  
Date Published: 2017-09-01
Start Page: 913
End Page: 927
Language: English
DOI: 10.2217/imt-2017-0052
PROVIDER: scopus
PMCID: PMC5810850
PUBMED: 29338609
DOI/URL:
Notes: Review -- Export Date: 2 October 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Takashi   Eguchi
    57 Eguchi
  2. Hua Zheng
    3 Zheng
Related MSK Work